Effects of high doses of recombinant human follicle-stimulating hormone in the treatment of male factor infertility: results of a pilot study

We performed a randomized double-blind placebo-controlled study on seminal parameters and endocrine profile of 30 normogonadotropic patients with male factor infertility to assess the efficacy of treatment with recombinant human FSH (rhFSH) at high doses (300 IU on alternate days) for a period of ≥4 months. The treatment induced a marked increase in sperm count, a slight increase in sperm motility, no change in sperm morphology, and an evident increase only in FSH serum levels, showing that a prolonged treatment with rhFSH at high doses led to an evident improvement of sperm count in normogonadotropic infertile patients with idiopathic oligoasthenozoospermia.